Bryant Furlow

New Mexico

Public Health Reporter at The Lancet

Biologist turned investigative health care and science reporter. The Lancet, New Mexico In Depth, ProPublica LRN, Northwestern Univ Data Driven Reporting fellow

Featured in: Favicon

pulmonologyadvisor.com Favicon

nih.gov

salon.com

propublica.org Favicon

medscape.com Favicon

charlotteobserver.com Favicon

thelancet.com Favicon

newsobserver.com Favicon

abqjournal.com Favicon

govexec.com + 49 more

Articles

Climate change fuels deadly dust storms worldwide

2 weeks ago | thelancet.com | Bryant Furlow

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
Natural Disasters and Cancer Care: How to Reduce Disruptions and Protect Patients

1 month ago | hematologyadvisor.com | Bryant Furlow

The recent wildfires in Los Angeles are just the latest in a series of natural disasters that have disrupted cancer care.1-5 As these disasters become more and more common, experts are recommending that cancer centers and other health care facilities take steps to prevent or reduce disruptions in care and lower risks for patients.
Test Can Predict Post-HCT Relapse in AML and MDS

1 month ago | hematologyadvisor.com | Bryant Furlow

The AlloHeme test can be used to predict relapse after allogeneic hematopoietic cell transplant (HCT) in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), according to results from the ACROBAT trial presented at the Tandem Meetings 2025. AlloHeme is a chimerism-monitoring test with a limit of detection of 0.016%, said study presenter Monzr M. Al Malki, MD, of the City of Hope Cancer Center in Duarte, California.
Chemical industry lobbyists will run chemical safety oversight at US EPA

1 month ago | thelancet.com | Bryant Furlow

The Trump administration is putting lobbyists and attorneys from the petroleum and chemical industries into leadership positions at the US Environmental Protection Agency (EPA). Several of these individuals have worked for years to weaken regulation of cancer-causing products.
Trem-Cel May Help Reduce Toxicity of Gemtuzumab Ozogamicin in AML

1 month ago | hematologyadvisor.com | Bryant Furlow

Tremtelectogene empogeditemcel (trem-cel) may make gemtuzumab ozogamicin maintenance safer for patients with high-risk acute myeloid leukemia (AML), according to results of a phase 1/2 trial presented at the Tandem Meetings 2025. Researchers found that trem-cel — a CD33-deleted allograft — allowed patients to receive gemtuzumab ozogamicin maintenance at therapeutic doses without high risks of hematologic and liver toxicities.
Bone Marrow Transplant Linked to Accelerated Brain Aging, Cognitive Decline

1 month ago | hematologyadvisor.com | Bryant Furlow

Bone marrow transplant (BMT) is associated with accelerated brain aging and worse neurocognitive functioning in patients with hematologic malignancies, according to research presented at Tandem Meetings 2025. “BMT survivors do experience significant cognitive decline following transplant, with evidence of brain age acceleration compared to healthy controls,” said study presenter Noha Sharafeldin, MD, of the University of Alabama at Birmingham.
Is PTCy-Based GVHD Prophylaxis Better Than MMF-Based Prophylaxis?

1 month ago | hematologyadvisor.com | Bryant Furlow

Post-transplant cyclophosphamide (PTCy) plus sirolimus and cyclosporine can improve some outcomes when compared to mycophenolate mofetil (MMF) plus sirolimus and cyclosporine as graft-vs-host disease (GVHD) prophylaxis, according to phase 2 data presented at Tandem Meetings 2025. Researchers found that PTCy-based prophylaxis improved 1-year chronic GVHD-free, relapse-free survival (CRFS) and reduced the risk of moderate to severe chronic GVHD.
Measles outbreak challenges Trump's public health vision

1 month ago | thelancet.com | Bryant Furlow

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
Measles outbreak challenges Trump's public health vision

1 month ago | thelancet.com | Bryant Furlow

As the Trump administration targets federal public health agencies for mass firings and censorship, a growing outbreak of the airborne measles virus is raging across west Texas, imperilling the USA's measles-elimination status. As of Feb 24, 2025, Texas officials reported 90 cases and more than a dozen hospitalisations. They warned there could be hundreds of other, unidentified cases.
Test Can Predict Post-HCT Relapse in AML and MDS

1 month ago | cancertherapyadvisor.com | Bryant Furlow

The AlloHeme test can be used to predict relapse after allogeneic hematopoietic cell transplant (HCT) in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), according to results from the ACROBAT trial presented at the Tandem Meetings 2025. AlloHeme is a chimerism-monitoring test with a limit of detection of 0.016%, said study presenter Monzr M. Al Malki, MD, of the City of Hope Cancer Center in Duarte, California.